A landmark decision by the US Supreme Court on June 25 has reshaped Bayer’s legal landscape, stripping thousands of future glyphosate lawsuits of their legal foundation. The stock responded with its biggest weekly surge in years, closing at €46.61 on Friday — a gain of nearly 23% over the week and an 82% advance year-to-date. But beneath the euphoria, the stock’s relative strength index sits at 80.6, technically overbought, and more than 23% above its 50-day moving average. The question now is whether the rally marks the start of a sustained re-rating or merely a relief pop that needs operational proof to hold.
The Supreme Court’s ruling in the Durnell case bars individual states from mandating their own cancer warnings on glyphosate products. For Bayer, that ends nearly a decade of legal uncertainty tied to Roundup. Investment banks wasted no time updating their models. Goldman Sachs reiterated its “Buy” rating with a €55 price target. Jefferies lifted its target from €40 to €46 but kept a “Hold”. Bank of America called the verdict a “Big Win”. Sadif Investment Analytics stood alone with “Sell”, warning the balance sheet remains too weak to justify the current valuation.
Yet the legal relief faces its first real test on July 9, when a Missouri court holds a final hearing on a $7.25 billion settlement Bayer reached with glyphosate plaintiffs in February. The agreement has already received preliminary approval, but some plaintiff attorneys have voiced sharp criticism. Should the hearing go smoothly, the costliest litigation in Bayer’s history would be largely resolved. If it falters, the rally’s central thesis — that legal risk is collapsing — would be severely undermined.
Even as the courtroom drama plays out, Bayer’s pharmaceutical pipeline provides a second catalyst. Asundexian, the company’s stroke prevention candidate, is running through three parallel approval processes. The European Medicines Agency has initiated its central assessment. The US Food and Drug Administration accepted the application in May and granted Priority Review, based on the pivotal OCEANIC-STROKE study in which Asundexian reduced ischemic strokes by 26% versus placebo without raising bleeding risk. China has also granted Priority Review. Success in all three markets would give Bayer a regulatory lead over Bristol Myers Squibb and Johnson & Johnson’s competing candidate, Milvexian.
The third near-term catalyst arrives on August 4, when Bayer reports second-quarter results. CFO Judith Hartmann, who succeeded Wolfgang Nickl on June 1, will present the first updated outlook on debt and cash flow following the Supreme Court decision. The quiet period runs from July 15 to August 4. Analysts expect quarterly revenue of about €10.7 billion in what is typically a softer summer period.
Should investors sell immediately? Or is it worth buying Bayer?
None of this obscures the structural strain Bayer still carries. Net financial debt stood at nearly €30 billion at year-end 2025, a reduction of 8.5% from 2024 that was largely driven by currency effects. Free cash flow fell 32.9% to €2.1 billion in 2025, and management expects a negative free cash flow for full-year 2026 as litigation payouts continue to drain resources. Around €5 billion is expected to flow out in 2026 alone for ongoing legal cases.
Additional headwinds come from Washington. The US administration is investigating German drug pricing, and initial tariffs on pharmaceutical products could be imposed as early as late July 2026, with a formal hearing scheduled for September. A separate ongoing settlement process in Missouri remains open, adding complexity to the legal picture.
Away from litigation and politics, Bayer is investing in innovation. The company struck a research partnership with Iambic Therapeutics, a US firm whose AI platforms will help identify new drug candidates and strengthen Bayer’s early-stage pipeline.
The market’s near-term direction now hinges on two pivotal weeks. If the Missouri settlement holds on July 9 and Asundexian navigates its regulatory reviews without setbacks, the stock’s current valuation may prove durable, with the 52-week high of €49.93 serving as a natural next target. Conversely, if the settlement collapses or any regulator signals concerns about the stroke drug, the overbought stock could correct sharply despite Supreme Court tailwinds. For now, the rally is priced for a clean outcome — the next two weeks will reveal whether that bet is well placed.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 29 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 29.
Bayer: Buy or sell? Read more here...
